EOG as a monitor of desferrioxamine retinal toxicity.
Iron overload caused by blood transfusion-dependent anaemia usually results in lethal cardiac toxicity unless treated by iron-chelation therapy. Chelation therapy with desferrioxamine (DFO) is well established and widely used to remove excess iron. Unfortunately, visual disorders have been recorded after DFO infusion. In this investigation, a 61-year-old Caucasian female received DFO for her autoimmune haemolytic anaemia. Prior to starting with the DFO treatment, her baseline ophthalmic screening and electrooculogram (EOG) were completely normal. Two years later she noticed a grey scotoma in her right eye. Visual acuity in this eye was reduced from 6/5 to 6/9 and funduscopy revealed evidence of non-specific mottling of the retinal pigment epithelium of both retinae. The EOG was flat (106%) in the right eye and subnormal in the left (155%). The lower limit of our EOG Arden Ratio for normal subjects is 180%. After her DFO treatment was stopped, her right visual acuity returned to 6/5, her field tests showed progressive improvement bilaterally and the EOG went back to the normal range. While waiting for splenectomy, the patient was restarted on a lower dose of DFO and EOG measurements were carried out every two (or three) weeks to monitor for DFO toxicity. The EOG varied during this period indicating some deterioration of function in the retinal pigment epithelium. However, normalisation of the EOG values (right = 217%, left = 217%) occurred after splenectomy and cessation of DFO therapy. Her visual function was normal and her visual acuity 6/4 bilateral when she was discharged from our outpatient clinic. On reviewing her history it was apparent that the EOG was the most sensitive indicator of DFO toxicity.
Hidajat
Rudy R
RR
Department of Ophthalmology, Christchurch Hospital, Christchurch, New Zealand. rudy.hidajat@cdhb.govt.nz
McLay
Jan L
JL
Goode
David H
DH
Spearing
Ruth L
RL
D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy; D003676:Deferoxamine / Q000009:adverse effects*; D004585:Electrooculography; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects*; D008875:Middle Aged; D008991:Monitoring, Physiologic; D012160:Retina / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D012164:Retinal Diseases / Q000139:chemically induced* / Q000175:diagnosis* / Q000503:physiopathology; D012607:Scotoma / Q000139:chemically induced / Q000175:diagnosis / Q000503:physiopathology; D014792:Visual Acuity / Q000187:drug effects; D014794:Visual Fields
D007502:Iron Chelating Agents; D003676:Deferoxamine